Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
International Journal of Geriatric Psychiatry|February 20, 2014
Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysisGustavo Alva, Richard Isaacson, Carl Sadowsky, et al.The Psychiatric Quarterly|June 13, 2025
Sociodemographic Disparities in the Relationship between Living Alone and Suicide Ideation among Older AdultsPing-I Lin, James R John, George Grossberg, et al.Journal of the American Medical Directors Association|January 15, 2022
Using Telemedicine to Assess and Manage Psychosis in Neurodegenerative Diseases in Long-Term CareLynn Shaughnessy, Stephen Brunton, Craig Chepke, et al.International Psychogeriatrics|January 26, 2010
Management of behavioral problems in Alzheimer's diseaseSerge Gauthier, Jeffrey Cummings, Clive Ballard, et al.American Journal of Alzheimer'S Disease and Other Dementias|August 29, 2013
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's diseaseGeorge Grossberg, Jeffrey Cummings, Lutz Frölich, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 16, 2008
Personal perspectives of persons with Alzheimer's disease and their carers: a global surveyAlexander Kurz, Mary Schulz, Peter Reed, et al.International Journal of Geriatric Psychiatry|March 24, 2007
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsuleBengt Winblad, Jeffrey Cummings, Niels Andreasen, et al.Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 22, 2021
Development and assessment of a brief screening tool for psychosis in dementiaJeffrey L Cummings, Zahinoor Ismail, Bradford C Dickerson, et al.Journal of Medical Economics|December 11, 2023
A real-world assessment of healthcare costs associated with agitation in Alzheimer's dementiaGeorge Grossberg, Annette Urganus, Jeff Schein, et al.Alzheimer Disease and Associated Disorders|June 3, 2009
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extensionGeorge Grossberg, Carl Sadowsky, Hans Fröstl, et al.Pageof 4